PMID- 30246213
OWN - NLM
STAT- MEDLINE
DCOM- 20190117
LR  - 20211122
IS  - 2737-5935 (Electronic)
IS  - 0037-5675 (Print)
IS  - 0037-5675 (Linking)
VI  - 59
IP  - 11
DP  - 2018 Nov
TI  - Is cryosurgery a feasible local therapy for bone metastatic prostate cancer?
PG  - 584-589
LID - 10.11622/smedj.2018119 [doi]
AB  - INTRODUCTION: This study aims to assess whether cryosurgery is a feasible local 
      therapy for bone metastatic prostate cancer (bmPCa). METHODS: A total of 23 
      patients with bmPCa who received cryosurgery and adjuvant androgen deprivation 
      therapy (ADT) were included in the cryosurgery group (Group 1). Another 23 
      matched patients who received only ADT served as the control (Group 2). 
      Prostate-specific antigen (PSA) nadir level, time to PSA nadir, time to 
      castration-resistant prostate cancer (CRPC), progression-free survival and 
      therapy response of bone metastases were compared between the groups. RESULTS: 
      The median follow-up time in Group 1 and Group 2 patients was 37 (range 19-53) 
      months and 42 (range 24-56) months, respectively. Patients in Group 1 had fewer 
      local complications, lower PSA nadir level (0.23 ng/mL vs. 4.01 ng/mL; p = 
      0.024), shorter median time to PSA nadir (3 months vs. 7 months; p < 0.001), 
      longer median time to CRPC (36 months vs. 27 months; p = 0.002) and longer 
      progression-free survival (35 months vs. 26 months; p = 0.003) compared to those 
      in Group 2. Therapy responses of bone metastases were similar in the two 
      treatment groups (p = 0.689). CONCLUSION: Cryosurgery is a feasible local therapy 
      for bmPCa patients with prostate volume less than 50 mL and without bulk tumours 
      outside the prostate capsula. Cryosurgery may decrease PSA nadir level, local 
      complications and time to PSA nadir, delay time to CRPC and improve 
      progression-free survival.
CI  - Copyright: (c) Singapore Medical Association.
FAU - Sheng, Mingxiong
AU  - Sheng M
AD  - Department of Urology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
AD  - Department of Urology, Mindong Hospital affiliated to Fujian Medical University, 
      Fuan, Fujian, People's Republic of China.
FAU - Wan, Lingling
AU  - Wan L
AD  - Department of Urology, Mindong Hospital affiliated to Fujian Medical University, 
      Fuan, Fujian, People's Republic of China.
FAU - Liu, Changming
AU  - Liu C
AD  - Department of Urology, Mindong Hospital affiliated to Fujian Medical University, 
      Fuan, Fujian, People's Republic of China.
FAU - Liu, Chunxiao
AU  - Liu C
AD  - Department of Urology, Zhujiang Hospital of Southern Medical University, 
      Guangzhou, Guangdong, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20180924
PL  - India
TA  - Singapore Med J
JT  - Singapore medical journal
JID - 0404516
RN  - EC 3.4.21.- (KLK3 protein, human)
RN  - EC 3.4.21.- (Kallikreins)
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Biopsy
MH  - Bone Neoplasms/*secondary/*surgery
MH  - *Cryosurgery
MH  - Disease Progression
MH  - Humans
MH  - Kallikreins/blood
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/surgery
MH  - Prostate/pathology
MH  - Prostate-Specific Antigen/blood
MH  - Prostatic Neoplasms/*pathology/*surgery
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC6250764
OTO - NOTNLM
OT  - bone and bones
OT  - cryosurgery
OT  - neoplasm metastasis
OT  - prostatic neoplasms
EDAT- 2018/09/25 06:00
MHDA- 2019/01/18 06:00
PMCR- 2018/11/01
CRDT- 2018/09/25 06:00
PHST- 2018/09/25 06:00 [pubmed]
PHST- 2019/01/18 06:00 [medline]
PHST- 2018/09/25 06:00 [entrez]
PHST- 2018/11/01 00:00 [pmc-release]
AID - j59/11/584 [pii]
AID - SMJ-59-584 [pii]
AID - 10.11622/smedj.2018119 [doi]
PST - ppublish
SO  - Singapore Med J. 2018 Nov;59(11):584-589. doi: 10.11622/smedj.2018119. Epub 2018 
      Sep 24.